Loading...
•
Dec 31, 2022
Zimmer Biomet Q4 2022 Earnings Report
Reported a strong fourth quarter, driven by solid execution and innovation, amidst continued post-pandemic recovery.
Key Takeaways
Zimmer Biomet reported a 2.7% increase in fourth-quarter net sales from continuing operations, reaching $1.825 billion, with an 8.3% increase on a constant currency basis. The diluted loss per share was $0.62, while adjusted diluted earnings per share were $1.88. The company is providing full-year 2023 financial guidance.
Fourth quarter net sales from continuing operations of $1.825 billion increased 2.7% and 8.3% on a constant currency basis
Fourth quarter diluted loss per share from continuing operations was $0.62; adjusted diluted earnings per share from continuing operations were $1.88
Full-year net sales from continuing operations of $6.940 billion increased 1.6% and 6.6% on a constant currency basis
Full-year diluted earnings per share from continuing operations were $1.38; adjusted diluted earnings per share from continuing operations were $6.89
Revenue by Segment
Forward Guidance
The Company is providing the following full-year 2023 financial guidance: Projected Year Ending December 31, 2023 2023 Reported Revenue Change 1.5% - 3.5% Foreign Currency Exchange Impact (1.5)% Adjusted Diluted EPS(1) $6.95 - $7.15
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...